ReviewSemergen2020
[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]
Review in Semergen, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Optimizing blood pressure control through telemedicine in Primary Care in Spain (Iniciativa Óptima): Results from a Delphi study].Atencion primaria · 2022Guideline
- [COVID-19 and thromboprophylaxis: Recommendations for our clinical practice in Primary Care].Semergen · 2020Guideline
- Evolution of Anxiety, Emotional Intelligence, and Effective Personality after COVID-19 among Spanish University Students.Behavioral sciences (Basel, Switzerland) · 2024Article
- [Depressive Symptoms in Healthcare Workers Two Years After the Start of the COVID-19 Pandemic in Bogotá, Colombia].Revista colombiana de psiquiatria · 2023Article
- The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.Veterinary world · 2021Review
- Evolution of a Cohort of COVID-19 Infection Suspects Followed-Up from Primary Health Care.Journal of personalized medicine · 2021Article
- [Possible protective factors of SARS-CoV-2 infection in a vulnerable patient: Report of a case].Semergen · 2020Article
- [Heart Failure hospitalization during COVID-19 pandemic].Semergen · 2020Article
- Science mapping of COVID-19 contributions in primary health care by OECD countries: A machine learning approach.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic is a global health emergency and we need to know more about it. Patients with cardiovascular risk and previous kidney risk have been identified as especially vulnerable for greater morbidity and mortality when they suffer from COVID-19. A considerable proportion of patients can develop a vascular lesion in the context of the disease that entails a greater lethality. Cardiovascular and renal complications represent a problem and, probably in the near future, may pose a threat to patients who have survived COVID-19. As physicians, we cannot forget that during an epidemic like this, other chronic diseases are present, and patients continue to require care. We are obliged to monitor even more intensely their treatments and control degree. Furthermore, we must not forget that urgent situations continue to arise in this pandemic situation and require prompt attention. In this current situation, it is very likely that many patients, out of fear, have not sought medical attention. The situation during the epidemic and the uncertainty of the post-COVID-19 period, requires intensification in the control and monitoring of cardiovascular and kidney disease in our patients. Primary care constitutes a key level of care for the care of the population with cardiovascular disease. Likewise, and in the face of this new health scenario, we need to promote the prevention and control measures that emanate from the studies currently underway. Now, more than ever, we need research, crucial to improve the cardiovascular and renal prognosis of our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.